JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

Benzinga Newsdesk www.benzinga.com Positive 83.0%

Neg 0% Neu 0% Pos 83%

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $425.